Emergent BioSolutions Investor Relations Material

Emergent BioSolutions Inc. is a specialty pharmaceutical company that focuses on the development, manufacture and commercialization of vaccines and therapeutics. The Company's products consist of anthrax vaccine (BioThrax (Anthrax Vaccine Adsorbed)), the only Food and Drug Administration (FDA) approved vaccine for the prevention of anthrax infection; other vaccines in development, including Vaxchora for the prevention of cholera; NuThrax for the treatment of anthrax infection in combination with antibiotics; ACAM100, a smallpox vaccine for biodefense use, and AIGIV, a rabies vaccine candidate for pre- and post-exposure prophylaxis.